Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

医学 转移性乳腺癌 乳腺癌 临床终点 内科学 化疗 肿瘤科 腋窝淋巴结 癌症 随机对照试验 外科
作者
Rajendra Achyut Badwe,Rohini W. Hawaldar,Nita Sukumar Nair,Rucha Vishal Kaushik,Vani V. Parmar,Shabina Siddique,Ashwini Narsingrao Budrukkar,Indraneel Mittra,Sudeep Gupta
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (13): 1380-1388 被引量:642
标识
DOI:10.1016/s1470-2045(15)00135-7
摘要

Background The role of locoregional treatment in women with metastatic breast cancer at first presentation is unclear. Preclinical evidence suggests that such treatment might help the growth of metastatic disease, whereas many retrospective analyses in clinical cohorts have suggested a favourable effect of locoregional treatment in these patients. We aimed to compare the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation. Methods In this open-label, randomised controlled trial, we recruited previously untreated patients (≤65 years of age with an estimated remaining life expectancy of at least 1 year) presenting with de-novo metastatic breast cancer from Tata Memorial Centre, Mumbai, India. Patients were randomly assigned (1:1) to receive locoregional treatment directed at their primary breast tumour and axillary lymph nodes, or no locoregional treatment, by a computer-generated block randomisation sequence (block size of four). Randomisation was stratified by site of distant metastases, number of metastatic lesions, and hormone receptor status. Patients with resectable primary tumour in the breast that could be treated with endocrine therapy were randomly assigned upfront, whereas those with an unresectable primary tumour were planned for chemotherapy before randomisation. Of the patients who had chemotherapy before randomisation, we randomly assigned patients who had an objective tumour response after six to eight cycles of chemotherapy. The primary endpoint was overall survival analysed by intention to treat. This study is registered with ClinicalTrials.gov, NCT00193778. Findings Between Feb 7, 2005, and Jan 18, 2013, of the 716 women presenting with de-novo metastatic breast cancer, we randomly assigned 350 patients: 173 to locoregional treatment and 177 to no locoregional treatment. At data cut-off of Nov 1, 2013, median follow-up was 23 months (IQR 12·2–38·7) with 235 deaths (locoregional treatment n=118, no locoregional treatment n=117). Median overall survival was 19·2 months (95% CI 15·98–22·46) in the locoregional treatment group and 20·5 months (16·96–23·98) in the no-locoregional treatment group (HR 1·04, 95% CI 0·81–1·34; p=0·79), and the corresponding 2-year overall survival was 41·9% (95% CI 33·9–49·7) in the locoregional treatment group and 43·0% (35·2–50·8) in the no locoregional treatment group. The only adverse event noted was wound infection related to surgery in one patient in the locoregional treatment group. Interpretation There is no evidence to suggest that locoregional treatment of the primary tumour affects overall survival in patients with metastatic breast cancer at initial presentation who have responded to front-line chemotherapy, and this procedure should not be part of routine practice. Funding Department of Atomic Energy, Government of India.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小鱼关注了科研通微信公众号
刚刚
枫叶完成签到,获得积分10
1秒前
西瓜汁发布了新的文献求助10
1秒前
1秒前
李健的应助被Lu采纳,获得10
1秒前
上官若男的应助被科研通管家采纳,获得10
2秒前
drizzle发布了新的文献求助10
2秒前
华仔的应助被科研通管家采纳,获得10
2秒前
科目三的应助被科研通管家采纳,获得10
2秒前
Ava的应助被科研通管家采纳,获得10
2秒前
隐形曼青的应助被科研通管家采纳,获得10
3秒前
3秒前
null的应助被科研通管家采纳,获得10
3秒前
Akim的应助被kaia采纳,获得10
3秒前
打打的应助被科研通管家采纳,获得10
3秒前
Hello的应助被科研通管家采纳,获得10
3秒前
3秒前
无极微光的应助被科研通管家采纳,获得20
3秒前
顾矜的应助被科研通管家采纳,获得10
3秒前
fan的应助被科研通管家采纳,获得20
3秒前
钟小先生完成签到 ,获得积分10
3秒前
汉堡包的应助被科研通管家采纳,获得10
4秒前
DW的应助被科研通管家采纳,获得10
4秒前
王富贵发布了新的文献求助10
4秒前
脑洞疼的应助被科研通管家采纳,获得30
4秒前
完美世界的应助被科研通管家采纳,获得10
4秒前
4秒前
科目三的应助被科研通管家采纳,获得10
4秒前
pluto的应助被科研通管家采纳,获得10
4秒前
4秒前
乐空思的应助被科研通管家采纳,获得100
4秒前
汉堡包的应助被刘刘宇航采纳,获得10
4秒前
无花果的应助被科研通管家采纳,获得10
4秒前
所所的应助被科研通管家采纳,获得10
5秒前
5秒前
5秒前
pluto的应助被科研通管家采纳,获得10
5秒前
YZhu完成签到,获得积分10
5秒前
隐形曼青的应助被科研通管家采纳,获得10
5秒前
乐空思的应助被科研通管家采纳,获得100
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784